We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

5 hedge funds and large institutions have $282K invested in XTL Biopharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more capital invested

Capital invested by funds: $216K → $282K (+$66.1K)

25% more funds holding

Funds holding: 4 → 5 (+1)

0% more ownership

Funds ownership: 0.01% → 0.01% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$37K
2
CTC
Central Trust Company
Missouri
+$190

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$61
Name Holding Trade Value Shares
Change 		Change in
Stake
NI
1
Noked Israel
Israel
$201K – – –
Morgan Stanley
2
Morgan Stanley
New York
$80.3K +$37K +9,743 +96%
BNP Paribas Financial Markets
3
BNP Paribas Financial Markets
France
$303 – – –
CTC
4
Central Trust Company
Missouri
$203 +$190 +50 New
UBS Group
5
UBS Group
Switzerland
$55 -$61 -16 -53%

XTLB Hedge Fund Activity: Q4 2023 in Review

5 of the 6,864 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2023, worth a combined $282K — up 31% from $216K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $37K. The largest seller was UBS Group, cutting an estimated $61.

  • 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2023, up from 4 in Q3 2023.
  • Funds reported $282K of XTL Biopharmaceuticals stock for Q4 2023, up 31% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q4 2023 and 0 closed out, a net change of +1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $37K added.
  • The largest XTL Biopharmaceuticals seller in Q4 2023 was UBS Group, an estimated $61 sold.

Based on aggregated 13F filings for Q4 2023.